U.S. Markets closed
  • S&P Futures

    3,902.00
    -20.75 (-0.53%)
     
  • Dow Futures

    31,308.00
    -132.00 (-0.42%)
     
  • Nasdaq Futures

    11,842.25
    -93.25 (-0.78%)
     
  • Russell 2000 Futures

    1,763.70
    -9.10 (-0.51%)
     
  • Crude Oil

    108.42
    -1.17 (-1.07%)
     
  • Gold

    1,812.80
    -3.10 (-0.17%)
     
  • Silver

    21.31
    -0.24 (-1.11%)
     
  • EUR/USD

    1.0478
    +0.0012 (+0.1153%)
     
  • 10-Yr Bond

    2.8860
    -0.0820 (-2.76%)
     
  • Vix

    30.96
    +4.86 (+18.62%)
     
  • GBP/USD

    1.2347
    +0.0005 (+0.0407%)
     
  • USD/JPY

    128.2020
    -0.0950 (-0.0740%)
     
  • BTC-USD

    28,843.33
    -1,700.26 (-5.57%)
     
  • CMC Crypto 200

    642.17
    -28.51 (-4.25%)
     
  • FTSE 100

    7,438.09
    -80.26 (-1.07%)
     
  • Nikkei 225

    26,911.20
    0.00 (0.00%)
     

2 Cancer Stocks With Absurdly Low Valuations

·4 min read
2 Cancer Stocks With Absurdly Low Valuations
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

The potential for four or more interest rate hikes by the Federal Reserve over the course of 2022 has been weighing heavily on growth stocks of late. Investors are clearly pivoting toward safe havens like value and dividend stocks ahead of this perceived eventuality. Shares of the cancer specialists Adaptimmune Therapeutics (NASDAQ: ADAP) and Clovis Oncology (NASDAQ: CLVS) are both trading at absurdly low valuations following their steep downturns over the past several weeks.